Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today ↗

July 18, 2024

Via Benzinga

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

July 18, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Stock Is a Blockbuster Biopharma In the Making ↗

July 18, 2024

Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.

Via InvestorPlace

Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗

July 17, 2024

Via Benzinga

35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. ↗

July 11, 2024

Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement.

Via InvestorPlace

Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗

June 27, 2024

Via Benzinga

Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends ↗

June 12, 2024

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

May 17, 2024

Via Benzinga

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip? ↗

July 08, 2024

Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.

Via The Motley Fool

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO ↗

July 07, 2024

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.

Via Benzinga

Topics ETFs

$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

July 03, 2024

Via Benzinga

Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows ↗

July 01, 2024

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged.

Via Benzinga

Topics ETFs

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 01, 2024

Via Benzinga

Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio? ↗

June 30, 2024

The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 26, 2024

Via Benzinga

Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

June 24, 2024

On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21,

Via Benzinga

Topics Stocks

Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday? ↗

June 24, 2024

Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains...

Via Benzinga

Topics Stocks

Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears ↗

June 24, 2024

A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.

Via InvestorPlace

Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success ↗

June 24, 2024

The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare.

Via InvestorPlace

Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge ↗

June 24, 2024

Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and...

Via Benzinga

Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug ↗

June 24, 2024

The companies are working on treatments for ATTR amyloidosis with cardiomyopathy.

Via Investor's Business Daily

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

June 24, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Masters In Trading - Saturday, June 22 ↗

June 22, 2024

In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.

Via Talk Markets

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

June 14, 2024

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

June 13, 2024

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2024

Via Benzinga

Alnylam Issues 2023 Corporate Responsibility Report

May 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.